REDWOOD CITY, Calif., April 16 /PRNewswire-FirstCall/ -- Threshold Pharmaceuticals, Inc. (Nasdaq: THLD - News), today announced multiple presentations regarding its oncology pipeline, which includes two preclinical presentations on the Hypoxically Activated Prodrug, TH-302, and two research presentations from Threshold's Tubulin Inhibitor program. The presentations will take place at the 2007 American Association for Cancer Research (AACR) annual meeting being held April 14 - 18, 2007, at the Los Angeles Convention Center in Los Angeles, CA.
